MannKind Markets Afrezza to People with Type 1 Diabetes

The maker of inhaled insulin Afrezza is betting that relaunching their product and making it a success depends less on diabetics being afraid of needles and more on its clinical advantages over existing insulin.

Read more

Posted in Glucose & Insulin